
Sign up to save your podcasts
Or


This week on Biotech Nation, Priovant Therapeutics CEO Ben Zimmer shares how their once-a-day pill could transform the treatment of severe autoimmune diseases like dermatomyositis and non-infectious uveitis. With phase 3 trials in progress, Priovant is offering hope to patients with few modern treatment options.
By Moira Gunn4.1
2929 ratings
This week on Biotech Nation, Priovant Therapeutics CEO Ben Zimmer shares how their once-a-day pill could transform the treatment of severe autoimmune diseases like dermatomyositis and non-infectious uveitis. With phase 3 trials in progress, Priovant is offering hope to patients with few modern treatment options.

21,974 Listeners

43,864 Listeners

32,020 Listeners

30,707 Listeners

43,579 Listeners

707 Listeners

6,420 Listeners

30,216 Listeners

125 Listeners

321 Listeners

9,911 Listeners

34 Listeners

18 Listeners

48 Listeners

138 Listeners